ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted pill shows promise against rare lung cancer mutation
Disease control OngoingThis study tests a new daily pill, TAK-788, against standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 354 adults will be randomly assigned to receive either the pill …
Matched conditions: ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 16:27 UTC
-
New drug combo aims to extend life in advanced lung cancer
Disease control OngoingThis study tests whether adding eftilagimod alfa to standard immunotherapy and chemotherapy helps people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 756 adults who have not had prior treatment for their advanced disease will recei…
Matched conditions: ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC